Halia Therapeutics – Eliminating Chronic Inflammation by Targeting the NLRP3 Inflammasome
David Bearss, PhD, President and CEO at Halia Therapeutics, a clinical-stage biopharma company developing novel therapies to improve the lives of patien...
David Bearss, PhD, President and CEO at Halia Therapeutics, a clinical-stage biopharma company developing novel therapies to improve the lives of patien...
Schizophrenia is a serious and complex mental illness that left untreated can disrupt a person's relationships, physical health, and plans for the futur...
Mark McDonough, CEO of ChromaCode, a molecular diagnostics company, discusses how ChromaCode technology provides a cost-effective, rapid, and accurate...
Amelia Korangy, Director of External Affairs Strategy and Programs at ViiV Healthcare - the only pharmaceutical company solely focused on HIV, discusses...
Steve Marcus, CEO of Cantex Pharmaceuticals, a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other...
Greg Pierce, SVP and GM of Specialty, Health & Wellness at Synchrony, a financial services company, discusses the over-the-counter (OTC) hearing aids ru...
federal government designated May 11, 2023, as the official end of the COVID-19 health emergency in the U.S. Learn more on Health Professional Radio.
Amy Meyer, Manager of Primate Experimentation Campaigns for People for the Ethical Treatment of Animals (PETA) discusses what is happening to animals in...
Douglas Rex, MD, Distinguished Professor Emeritus at Indiana University School of Medicine and a full-time clinical gastroenterologist at Indiana Univer...
Elizabeth Garner, MD, Chief Scientific Officer for Ferring Pharmaceuticals discusses C. Learn more on Health Professional Radio.